GSK plc received a positive opinion from the EMA on July 29, 2024, for its RSV vaccine Arexvy, recommending its use in adults aged 50-59 at increased risk of RSV disease. If approved, this would make it the first vaccine available in the EU for this age group; the final decision is expected by September 2024.